about
Phospholipid binding of antiphospholipid antibodies and placental anticoagulant proteinCelecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I StudyTreatment of pregnant patients with antiphospholipid syndromeAspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individualsAnti-inflammatory and immunosuppressive drugs and reproductionEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialSafety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.Cardiovascular risk factors in the antiphospholipid syndromeAntiphospholipid Syndrome Clinical Research Task Force report.Lepromatous leprosy mimicking systemic lupus erythematosus: a clinical pathology conference held by the division of rheumatology at hospital for special surgery14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.Guidelines for the treatment of antiphospholipid syndrome.Antiphospholipid syndrome and cognition.The impact of Arthritis & Rheumatism in Latin America.Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide.Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.Cutting-edge issues in autoimmune uveitis.Management of obstetric antiphospholipid syndrome.Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?Putting the value into biosimilar decision making: the judgment value criteria.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay.Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.Antiphospholipid syndrome and antibodies.Clotting, immune system, and venous thrombosis in lung adenocarcinoma patients: a prospective study.The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis.[Lucio phenomenon. Vasculitis or occlusive vasculopathy?].Translation, cross-cultural adaptation and validation of the Brazilian version of the Nonarthritic Hip Score.Contractile Cells and Fibrillin-1 Distribution is Disturbed in Terminal Villi of Placentae from Patients with Preeclampsia and Systemic Lupus ErythematosusFatty acid chain is a critical epitope for antiphospholipid antibodyIgG but not IgM anti-phospholipid antibody binding is temperature dependentLysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine bindsI latin american congress of autoimmunity galapagos--September 15-18Primary antiphospholipid nephropathy beginning during pregnancyAmputation of digits or limbs in patients with antiphospholipid syndromeLupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patientsLung adenocarcinoma and antiphospholipid antibodies
P50
Q28186234-5E255279-BE16-4F46-8869-E215B7841FF6Q28195282-BEB913A9-0C42-46AE-B75E-A24E178329EEQ28196925-8132003E-4ABA-4623-A4CF-FF75D8B951F7Q28217805-67686579-DD49-4EB6-A09B-0CCAC3F231C9Q28218219-48DBD0A2-A7AE-47AD-9CA1-37C496477163Q28304807-94A20CCC-1EF2-4D56-9930-0B97BD940A04Q30580226-54A6E174-8645-4DB0-ABAC-AC51268A2518Q30645037-754DB63B-95E2-4FB6-B9DF-8A2C49432E81Q33420116-80D61242-B93D-4D09-B09C-9D21C2DE9465Q34003460-79A457E5-A013-44F3-B4EC-FE189DC07BE0Q34163321-7CD44607-D4E0-4C5E-B297-DDE8B07C1F49Q34226644-DC0CDA13-A288-422F-A28D-CDCBE2BA08B4Q34400373-87863558-2EAD-437D-8BF8-1B5C436470BCQ34821893-9D1FBF20-1AA2-4248-852E-81F98C359FF3Q36960942-8895626E-D1BA-44FD-8E92-76A69F9E7B93Q37073742-C4EB730D-0C66-44F2-B2F1-D24CE185C8D0Q37510479-8A407FF2-8460-47BA-96C3-1E7B9F954A87Q37715948-CEF3B05C-4D36-47E3-A18A-5F57C8E3B762Q37931096-C3F1990E-5244-4D99-A7F3-7E80B3D23A46Q37959314-787C6A10-E3D9-4F96-9ADD-A6DA72314A51Q38161813-C46EF088-D2D9-4FE6-AF4D-6A4DCF33918EQ38175887-20C57C3D-3858-4982-94E7-0DCE76B9C68FQ38179720-7EBF218C-4066-4211-A63F-F3C814ED87ACQ38205079-39974455-1B33-4525-938F-014F894FD956Q40522677-C29A1163-A3D7-415A-A3A0-F28C2458DE7CQ41919391-4D8B58B6-1980-40BD-8177-CB8DE3CAFF5FQ42855490-E481E372-48F5-48C2-8F67-86F1C18A3432Q43411494-A457B9F5-19EB-495F-8CA4-D618E1B46831Q46315131-B09D9FB1-DDC9-4E02-B800-CD0D98A915CDQ46937726-926D235B-4090-43A0-9071-48E9817EE48AQ47708653-D53DC1CA-A8CE-4E92-8123-2488235B4794Q62911418-56B820CB-DA7A-4F94-9D21-176FC5118F11Q67663521-18BB447D-0526-485F-B64B-FCDAC099C3E1Q68437321-4196B771-3D5F-4C33-AC4B-D4DBFFFE10B1Q68557135-64DE45B7-985F-4101-8E08-B880B584FE0CQ75827764-CF62D3BB-0292-4B1F-92C4-0FD65FE71F14Q79190262-6CE5CA8B-B055-41FE-BF14-21FDA272A6B7Q80517057-A4A28D42-B44E-413E-8483-7D58C98E97EEQ81097537-25723B8D-B441-4EEA-81EC-3BDF296DA238Q83277719-B945F64D-05DF-4135-9A5B-90CA07702C42
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roger Levy
@ast
Roger Levy
@en
Roger Levy
@es
Roger Levy
@nl
Roger Levy
@sl
Роджер Леви
@ru
type
label
Roger Levy
@ast
Roger Levy
@en
Roger Levy
@es
Roger Levy
@nl
Roger Levy
@sl
Роджер Леви
@ru
altLabel
RA Levy
@en
prefLabel
Roger Levy
@ast
Roger Levy
@en
Roger Levy
@es
Roger Levy
@nl
Roger Levy
@sl
Роджер Леви
@ru
P1053
K-3087-2014
P106
P1153
35398389300
P21
P31
P3829
P496
0000-0001-6393-6031